<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heparin dosing during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heparin dosing during pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Heparin dosing during pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Indication</td> <td class="subtitle1_left">Type of heparin</td> <td class="subtitle1_left">Dosing information</td> </tr> <tr> <td class="align_middle" rowspan="3">VTE prevention</td> <td class="align_middle" rowspan="2">LMW heparin</td> <td><strong>Low dose</strong> (also called prophylactic dose)<strong>:</strong> <ul> <li>Enoxaparin: <ul> <li>Weight &lt;100 kg: 40 mg SUBQ once daily</li> <li>Weight ≥100 kg: 60 mg SUBQ once daily</li> </ul> </li> <li class="none"><strong>or</strong></li> <li>Dalteparin: <ul> <li>Weight &lt;100 kg: 5000 units SUBQ once daily</li> <li>Weight ≥100 kg: 7500 units SUBQ once daily</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>Intermediate dose</strong><sup>*</sup><strong>:</strong> <ul> <li>Enoxaparin 40 mg SUBQ once daily, increase as pregnancy progresses and weight increases to 1 mg/kg once daily</li> <li class="none"><strong>or</strong></li> <li>Dalteparin 5000 units SUBQ once daily, increase as pregnancy progresses and weight increases to 100 units/kg once daily</li> </ul> </td> </tr> <tr> <td class="align_middle">UFH</td> <td><strong>According to trimester</strong><sup>¶</sup><strong>:</strong> <ul> <li>First trimester: 5000 to 7500 units SUBQ every 12 hours</li> <li>Second trimester: 7500 to 10,000 units SUBQ every 12 hours</li> <li>Third trimester: 10,000 units SUBQ every 12 hours</li> </ul> </td> </tr> <tr> <td class="align_middle" rowspan="2">VTE treatment (therapeutic dose)</td> <td class="align_middle">LMW heparin</td> <td> <p>Enoxaparin 1 mg/kg SUBQ every 12 hours</p> <p><strong>or</strong></p> Dalteparin 100 units/kg SUBQ every 12 hours</td> </tr> <tr> <td class="align_middle">UFH</td> <td>Can be given as a continuous IV infusion or SUBQ dose every 12 hours. Titrated to keep the aPTT in the therapeutic range.</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>This table applies to VTE in pregnant individuals, with the exception of individuals with a prosthetic heart valve, which is discussed separately in UpToDate.</p>
<ul class="decimal_heading">
<li><strong>Dose level</strong> – Prevention typically uses low or intermediate dose, but therapeutic dose may be used for prevention in selected cases (eg, individuals with recurrent unprovoked thrombotic events [with or without hereditary thrombophilia or antiphospholipid antibody syndrome] who are receiving long-term anticoagulation with warfarin or a direct oral anticoagulant such as rivaroxaban 20 mg daily or apixaban 5 mg twice daily).</li>
<li><strong>Choice of agent</strong> – LMW heparin is recommended for most patients. UFH is used when there may be a need for rapid discontinuation, such as for delivery or perioperatively or in individuals with severely reduced kidney function (eg, CrCl &lt;30 mL/min). Only one heparin product is given at any point in time. Confirm the absence of preservatives (eg, benzyl alcohol) in the heparin product chosen.</li>
</ul>
<p class="extra_spacing_top">Refer to UpToDate for anticoagulation indications, choice of dose level, duration of pharmacologic therapy, and timing of switches between LMW heparin and UFH.</p></div><div class="graphic_footnotes"><p>ACCP: American College of Chest Physicians; ACOG: American College of Obstetricians and Gynecologists; aPTT: activated partial thromboplastin time; CrCl: creatinine clearance; IV: intravenous; LMW: low molecular weight; SUBQ: subcutaneously; UFH: unfractionated heparin; VTE: venous thromboembolism.</p>
<p>* Our "intermediate" dose level differs from that used in society guidelines (eg, ACCP, ACOG). Some clinicians prefer to use a different "intermediate" dose level such as enoxaparin 40 mg SUBQ every 12 hours; however, this entails a significant increase in the number of injections over the course of the pregnancy.</p>
¶ Some clinicians use 5000 units SUBQ every 12 hours throughout the pregnancy; however, this dose may be insufficient in some patients.</div><div class="graphic_reference">Courtesy of Kenneth A Bauer, MD; updated with data from:
<ol>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
<li>Bistervels IM, Buchmüller A, Wiegers HMG, et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): An open-label, multicentre, randomised, controlled trial. Lancet 2022; 400:1777.</li>
</ol></div><div id="graphicVersion">Graphic 140440 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
